FDA follow-on biologics workshop
FDA schedules public workshop on "follow-on protein products" for Sept. 14 and 15. "Because of the scientific complexity of protein pharmaceutical products, FDA intends to conduct an extensive public dialogue on the scientific issues relating to the development and approval of such products," the 1FDA notice of the workshop states. The workshop will not address legal or regulatory issues. An FDA/DIA meeting on follow-on biologics is expected to take place in 2005 (2"The Pink Sheet" Aug. 9, 2004, p. 10). The workshop will be held at the University of Maryland Shady Grove Conference Center in Rockville, Md. starting at 8:30 a.m. on Sept. 14 and at 8 a.m. on Sept. 15...
You may also be interested in...
Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.